While either NANOG expression or double-positive expression of NANOG and SOX2 were significantly correlated with improved survival rates in patients harboring pharyngeal tumors, none of these factors showed any impact on the clinical outcome of patients with laryngeal tumors. This evidence concerns the gene NANOG and pharynx neoplasm.